Idorsia Appoints Srishti Gupta, MD, As The New Chief Executive Officer To Secure Long-Term Success

Idorsia Ltd has announced the appointment of Dr. Srishti Gupta as Chief Executive Officer, effective July 1, 2025. Dr. Gupta has been a member of the company’s Board of Directors since 2021, which has provided her with a strong understanding of Idorsia’s business, people, and portfolio. Her long-standing involvement with the company positions her well to take on this leadership role. Dr. Gupta brings more than 20 years of experience in global health and biopharmaceutical innovation. 

She is a physician by training and has built a career around advancing science-driven solutions in medicine, healthcare strategy, and system-level improvements. She spent 18 years at McKinsey & Company, where she held senior leadership roles in the pharmaceutical and global health practices. Over the years, she has advised numerous organizations on portfolio development, business strategy, and improving patient access to medicines. More recently, she has held leadership roles on the boards of biotech firms and global health initiatives, helping to translate scientific breakthroughs into practical benefits for patients.

Dr. Gupta holds an MD from Harvard Medical School, a Master’s in Public Policy from the Harvard Kennedy School, and both undergraduate and graduate degrees in biology from Harvard University. With this transition, current CEO André C. Muller will retire from his role on July 1, 2025, and will assume an advisory position to support a smooth handover. Muller has served as CEO since June 13, 2024, during which time he led the company through operational and financial restructuring, secured new funding, and played a key role in the commercial rollout of QUVIVIQ in the EUCAN region. He also helped reshape the U.S. operating model for both QUVIVIQ and TRYVIO with a strong focus on financial discipline.

Jean-Paul Clozel, Chairman of the Board of Idorsia, said in a statement, “There are not many people with the business acumen and ingenuity who could have found solutions to the financial difficulties we have experienced in recent times, but André has managed to turn the financial situation around, allowing Idorsia to hit a reset button. For this, I personally, and all stakeholders in Idorsia owe André a great debt of gratitude. With the commercial ramp-up of QUVIVIQ set to bring the company to profitability by the end of 2027, the focus must now return to the company’s portfolio. I believe that Srishti brings the perfect mix of scientific thinking, medical knowledge, and leadership qualities to advance the portfolio and ensure the long-term success of Idorsia.”

Srishti Gupta, MD and Board member of Idorsia, stated, “This is an exciting and important moment for Idorsia. QUVIVIQ is gaining strong traction in Europe, and it’s rewarding to see our work improve patients’ lives globally. We are re-activating our collaboration discussions for TRYVIO, and I believe we are in a very strong position with the removal of the REMS and the excellent early feedback we receive from prescribers. We have great commercial and research partnerships and now have the stability to accelerate our pipeline. I’m keenly aware that we must balance ambition with financial discipline which means we will make smart, focused investments in the most promising assets. I’m honored to step into this role and help drive our next chapter of success, for our teams, our investors and most importantly, for the patients who are counting on us.”

André C. Muller, Chief Executive Officer, stated, “It has not been an easy year, but it has been an honor to lead Idorsia through troubled waters and I am happy that the solutions implemented with our exceptional team, have put the company on the right track to success. Having worked closely with Srishti as a Board member over the past 4 years, I have absolute confidence in her and am committed to supporting a smooth transition of leadership and contributing to the long-term future of the company.”

Upon taking up her new role, Dr. Gupta will remain a member of Idorsia’s Board of Directors as an Executive Board member. However, she will step down from her role on the Nominating, Governance, and Compensation Committee. As of July 1, 2025, the Board will consist of Jean-Paul Clozel (Chairman), Mathieu Simon (Vice-Chairman and Lead Independent Director), Srishti Gupta (Executive Board member), Bart Filius (Chair of the NGCC), and Sandy Mahatme (Chair of the Finance and Audit Committee).